Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PVLA
Palvella Therapeutics, Inc. (PVLA) EV/Sales
As of 16 October 2026, Palvella Therapeutics, Inc. (PVLA) trades at a EV/Sales of 35.6×. Over the past ten years it has ranged from −2.1× (June 2023) to 48.6× (September 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 0.5× | (46.59%) |
| FY2022 | 0.9× | (78.16%) |
| FY2021 | 4.1× | 77.49% |
| FY2020 | 2.3× | 31.63% |
| FY2019 | 1.7× | 252.08% |
| FY2018 | 0.5× | (95.37%) |
| FY2017 | 10.6× | 89.18% |
| FY2016 | 5.6× | (67.44%) |
| FY2015 | 17.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | 0.2× | (55.93%) |
| Dec 2023 | 0.5× | — |
| Sep 2023 | −0.3× | — |
| Jun 2023 | −1.2× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)